155 related articles for article (PubMed ID: 16369744)
1. Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer.
Uemura H; Hasumi H; Kawahara T; Sugiura S; Miyoshi Y; Nakaigawa N; Teranishi J; Noguchi K; Ishiguro H; Kubota Y
Int J Clin Oncol; 2005 Dec; 10(6):405-10. PubMed ID: 16369744
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin II blocker decreases serum prostate specific antigen in hormone refractory prostate cancer.
Yamagishi T; Uemura H; Nakaigawa N; Noguchi K; Kubota Y
J Urol; 2005 Feb; 173(2):441. PubMed ID: 15643197
[No Abstract] [Full Text] [Related]
3. Therapeutic targeting of angiotensin II receptor type 1 to regulate androgen receptor in prostate cancer.
Takahashi S; Uemura H; Seeni A; Tang M; Komiya M; Long N; Ishiguro H; Kubota Y; Shirai T
Prostate; 2012 Oct; 72(14):1559-72. PubMed ID: 22430461
[TBL] [Abstract][Full Text] [Related]
4. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
[TBL] [Abstract][Full Text] [Related]
5. Treatment of androgen-independent, hormone-refractory prostate cancer with docetaxel in Japanese patients.
Miyoshi Y; Uemura H; Nakamura M; Hasumi H; Sugiura S; Makiyama K; Nakaigawa N; Kishida T; Ogawa T; Yao M; Kubota Y
Int J Clin Oncol; 2005 Jun; 10(3):182-6. PubMed ID: 15990966
[TBL] [Abstract][Full Text] [Related]
6. Renin-angiotensin system is an important factor in hormone refractory prostate cancer.
Uemura H; Hasumi H; Ishiguro H; Teranishi J; Miyoshi Y; Kubota Y
Prostate; 2006 Jun; 66(8):822-30. PubMed ID: 16482568
[TBL] [Abstract][Full Text] [Related]
7. Role of estrogens in the secondary hormonal manipulation of hormone refractory prostate cancer.
Siddiqui K; Abbas F; Biyabani SR; Ather MH; Talati J
J Pak Med Assoc; 2004 Sep; 54(9):445-7. PubMed ID: 15518364
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of baseline reverse transcriptase-PCR for prostate-specific antigen in men with hormone-refractory prostate cancer treated with chemotherapy.
Ross RW; Manola J; Hennessy K; Galsky M; Scher H; Small E; Kelly WK; Kantoff PW
Clin Cancer Res; 2005 Jul; 11(14):5195-8. PubMed ID: 16033836
[TBL] [Abstract][Full Text] [Related]
9. Prospective study of estramustine phosphate for hormone refractory prostate cancer patients following androgen deprivation therapy.
Hirano D; Minei S; Kishimoto Y; Yamaguchi K; Hachiya T; Yoshida T; Yoshikawa T; Endoh M; Yamanaka Y; Yamamoto T; Satoh Y; Ishida H; Okada K; Takimoto Y
Urol Int; 2005; 75(1):43-9. PubMed ID: 16037707
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group.
Canil CM; Moore MJ; Winquist E; Baetz T; Pollak M; Chi KN; Berry S; Ernst DS; Douglas L; Brundage M; Fisher B; McKenna A; Seymour L
J Clin Oncol; 2005 Jan; 23(3):455-60. PubMed ID: 15659491
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancer.
Kosaka T; Miyajima A; Takayama E; Kikuchi E; Nakashima J; Ohigashi T; Asano T; Sakamoto M; Okita H; Murai M; Hayakawa M
Prostate; 2007 Jan; 67(1):41-9. PubMed ID: 17044086
[TBL] [Abstract][Full Text] [Related]
13. Effects of a genistein-rich extract on PSA levels in men with a history of prostate cancer.
deVere White RW; Hackman RM; Soares SE; Beckett LA; Li Y; Sun B
Urology; 2004 Feb; 63(2):259-63. PubMed ID: 14972467
[TBL] [Abstract][Full Text] [Related]
14. Antiproliferative efficacy of angiotensin II receptor blockers in prostate cancer.
Uemura H; Nakaigawa N; Ishiguro H; Kubota Y
Curr Cancer Drug Targets; 2005 Aug; 5(5):307-23. PubMed ID: 16101380
[TBL] [Abstract][Full Text] [Related]
15. A retrospective review of combination chemohormonal therapy as initial treatment for locally advanced or metastatic adenocarcinoma of the prostate.
Amato RJ; Teh BS; Henary H; Khan M; Saxena S
Urol Oncol; 2009; 27(2):165-9. PubMed ID: 18367115
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer.
Rago RP; Einstein A; Lush R; Beer TM; Ko YJ; Henner WD; Bubley G; Merica EA; Garg V; Ette E; Harding MW; Dalton WS
Cancer Chemother Pharmacol; 2003 Apr; 51(4):297-305. PubMed ID: 12721757
[TBL] [Abstract][Full Text] [Related]
17. E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology.
Rubin MA; Mucci NR; Figurski J; Fecko A; Pienta KJ; Day ML
Hum Pathol; 2001 Jul; 32(7):690-7. PubMed ID: 11486167
[TBL] [Abstract][Full Text] [Related]
18. Hormonal sensitivity following endocrine withdrawal in hormone-refractory prostate cancer.
Nishiyama T; Terunuma M
Urol Int; 2000; 65(1):28-31. PubMed ID: 10965298
[TBL] [Abstract][Full Text] [Related]
19. Effect of docetaxel in patients with hormone-dependent prostate-specific antigen progression after local therapy for prostate cancer.
Goodin S; Medina P; Capanna T; Shih WJ; Abraham S; Winnie J; Doyle-Lindrud S; Todd M; DiPaola RS
J Clin Oncol; 2005 May; 23(15):3352-7. PubMed ID: 15738531
[TBL] [Abstract][Full Text] [Related]
20. Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer.
Machiels JP; Mazzeo F; Clausse M; Filleul B; Marcelis L; Honhon B; D'Hondt L; Dopchie C; Verschaeve V; Duck L; Verhoeven D; Jousten P; Bonny MA; Moxhon AM; Tombal B; Kerger J
J Clin Oncol; 2008 Nov; 26(32):5261-8. PubMed ID: 18794543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
